0001136261-20-000008.txt : 20200107 0001136261-20-000008.hdr.sgml : 20200107 20200107163014 ACCESSION NUMBER: 0001136261-20-000008 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200106 FILED AS OF DATE: 20200107 DATE AS OF CHANGE: 20200107 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mehra Raj CENTRAL INDEX KEY: 0001757892 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22245 FILM NUMBER: 20513620 MAIL ADDRESS: STREET 1: C/O SEELOS THERAPEUTICS, INC. STREET 2: 300 PARK AVENUE, 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001017491 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870449967 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: (646) 998-6475 MAIL ADDRESS: STREET 1: 300 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC. DATE OF NAME CHANGE: 20100914 FORMER COMPANY: FORMER CONFORMED NAME: NEXMED INC DATE OF NAME CHANGE: 19970311 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2020-01-06 0 0001017491 SEELOS THERAPEUTICS, INC. SEEL 0001757892 Mehra Raj C/O SEELOS THERAPEUTICS, INC. 300 PARK AVENUE, 12TH FLOOR NEW YORK NY 10022 1 1 1 0 See Remarks Stock Option (right to buy) 1.42 2020-01-06 4 A 0 731000 0 A 2030-01-06 Common Stock 731000 731000 D 1/4th of the shares subject to the option shall vest on January 6, 2021, and 1/4th of the shares subject to the option shall vest annually thereafter. President, Chief Executive Officer, Chairman of the Board of Directors and Interim Chief Financial Officer /s/ Raj Mehra, Ph.D. 2020-01-07